TYPHIM Vi Rx
Generic Name and Formulations:
Typhoid vaccine cell; surface purified Vi polysaccharide 25micrograms per 0.5mL; soln; for IM inj; contains phenol.
Sanofi Pasteur, Inc.
Indications for TYPHIM Vi:
Immunization against typhoid fever.
Give at least 2 weeks before expected exposure; may repeat every 2 years. Adults: 0.5mL IM once in deltoid.
≥2yrs: 0.5mL in deltoid or vastus lateralis.
Not for use in chronic carriers or patients with active infection.
Have epinephrine (1:1000) inj available. Immunocompromised states. Previous typhoid vaccination. Thrombocytopenia. Coagulopathies. Acute infection. Active febrile illness. Exposure to contaminated food and water should be avoided. Pregnancy (Cat.C). Nursing mothers.
Local reactions, malaise, headache, GI upset, myalgia, fever.
Multidose vials—contact manufacturer
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|